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Abstract
Background: The number of older people with multiple health problems is increasing worldwide. This creates a
strain on clinicians and the health service when delivering clinical care to this patient group, who themselves carry
a large treatment burden. Despite shared decision-making being acknowledged by healthcare organisations as a
priority feature of clinical care, older patients with multimorbidity are less often involved in decision-making when
compared with younger patients, with some evidence suggesting associated health inequalities. Interventions
aimed at facilitating shared decision-making between doctors and patients are outdated in their assessments of
today’s older patient population who need support in prioritising complex care needs in order to maximise quality
of life and day-to-day function.
Aims:
 To undertake feasibility testing of an intervention (‘VOLITION’) aimed at facilitating the involvement of older
patients with more than one long-term health problem in shared decision-making about their healthcare
during GP consultations.
 To inform the design of a fully powered trial to assess intervention effectiveness.
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: j.e.butterworth@exeter.ac.uk
1Exeter Collaboration for Academic Primary Care (APEx), University of Exeter
Medical School, Room 110, Smeall building, St Luke’s campus, Magdalen
Road, Exeter EX1 2LU, UK
Full list of author information is available at the end of the article
Butterworth et al. Pilot and Feasibility Studies           (2020) 6:161 
https://doi.org/10.1186/s40814-020-00699-7
(Continued from previous page)
Methods: This study is a cluster randomised controlled feasibility trial with qualitative process evaluation interviews.
Participants are patients, aged 65 years and above with more than one long-term health problem (multimorbidity),
and the GPs that they consult with. This study aims to recruit 6 GP practices, 18 GPs and 180 patients. The
intervention comprises two components: (i) a half-day training workshop for GPs in shared decision-making; and (ii)
a leaflet for patients that facilitate their engagement with shared decision-making. Intervention implementation will
take 2 weeks (to complete delivery of both patient and GP components), and follow-up duration will be 12 weeks
(from index consultation and commencement of data collection to final case note review and process evaluation
interview). The trial will run from 01/01/20 to 31/01/21; 1 year 31 days.
Discussion: Shared decision-making for older people with multimorbidity in general practice is under-researched.
Emerging clinical guidelines advise a patient-centred approach, to reduce treatment burden and focus on quality of
life alongside disease control. The systematic development, testing and evaluation of an intervention is warranted
and timely. This study will test the feasibility of implementing a new intervention in UK general practice for future
evaluation as a part of routine care.
Trial registration: CLINICAL TRIALS.GOV registration number NCT03786315, registered 24/12/18
Keywords: Primary care, Elderly, Older people, Multimorbidity, Shared decision-making, Patient involvement
Background
It is estimated that by 2032, there will be over 13.5 mil-
lion patients in the UK aged 65 years and over, an in-
crease of 50% when compared with 9 million in 2012
[36]. The prevalence of multimorbidity (more than one
long-term health condition) increases with age [1]; 58%
in people over 60 years compared with 14% in those
under 40 years [30, 42, 43]. In developed countries, the
prevalence of multimorbidity is also higher in females,
among those with lower socioeconomic status (SES) and
in minority ethnic groups [11, 45]. In those with lower
SES, it is more common for mental and physical illness
to co-exist. In addition, patients’ experiences of multi-
morbidity are affected by psychosocial and behavioural
factors and larger health inequalities have been observed
in vulnerable groups [39].
Consequences of ageing with multimorbidity include
functional decline with poor quality of life and high
healthcare costs [1, 26, 32]. The Department of Health
[15] reported that older patients (those aged 65 and
above) consult increasingly frequently (12–14 times/year
in 2008/2009 vs. 6–7 times in 1995). Healthcare practi-
tioners are often ‘medicalising’ the care of older people,
diagnosing and treating each condition separately with
new medication for example, and there are increasing
rates of polypharmacy and new diagnoses [16].
There is evidence that involvement in healthcare
decision-making is valued by older patients with multi-
morbidity [4, 9]. It is a means of effectively sharing the
burden of treatment and enabling a holistic approach to
clinical care [48]. Despite older patients typically express-
ing high levels of satisfaction with the care that they re-
ceive [7], they have been shown to be less frequently
involved in decision-making when compared with youn-
ger, healthier patients [49], and there is a lack of recent
evidence in this area. Therefore, whilst this patient group
are often in receipt of ‘good-quality care’, there are con-
cerns that this care is not currently meeting the complex
needs of older patients with multimorbidity [48]. In
addition, there is some evidence of an association between
a lack of involvement and health inequalities for this pa-
tient group, for example, reduced rates of referral for post-
menopausal bleeding and for hip pain [17, 28, 46].
Interventions aimed at facilitating shared decision-
making between doctors and patients have previously
focused on condition-specific clinical decisions. These in-
terventions are therefore outdated in their assessments of
today’s older patient population who often have complex
needs as a result of multimorbidity [23, 38]. Recent litera-
ture suggests that new interventions are required in order
to address older patients’ fundamental needs and life-
goals, to support these patients in prioritising treatment
options that maximise their quality of life and day-to-day
function [48].
National Institute for Health and Care Excellence
(NICE) guidance highlights the importance of delivering
good-quality clinical care that takes account of multi-
morbidity [34]. The World Health Organisation [51] and
UK health policy [14, 35] have identified shared
decision-making as a priority feature of good-quality
clinical care. Shared decision-making is a component of
patient-centred care and is associated with patient ad-
herence with treatment advice, satisfaction with health-
care and trust in the doctor [13, 20, 25, 37]. Policy
makers require further evidence-based guidance regard-
ing how to direct funding towards good quality clinical
care for older patients with multimorbidity when con-
sulting in general practice [5, 34].
An effective intervention in this area has the potential
to address health inequalities through the facilitation of
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effective, personalised care that addresses patients’ funda-
mental needs holistically. The intervention has the poten-
tial to achieve positive outcomes for both patients and
practitioners, along with reductions in primary healthcare
costs for the National Health Service. This study aims (a)
to feasibility test the delivery and evaluation of the inter-
vention ‘VOLITION’, and (b) to carry out process evalu-
ation of intervention and study procedures.
Objectives
Feasibility objectives
Feasibility objectives will assess:
 Capability to recruit and the resulting characteristics
of the sample
 Data collection processes
 Potential outcome measures
 Resource and capacity for study management and
intervention implementation
 Responses to the intervention by participants
(tentative, preliminary evaluation)
Process evaluation objectives
Process evaluation objectives will assess:
 Acceptability of the intervention to patients and GPs
 Acceptability of study procedures to practices and
participants
The feasibility and process evaluation findings will to-
gether inform strategies to address any challenges in trial
and intervention delivery. Findings will inform the de-
sign of a future fully powered, large-scale, randomised




This study is a cluster randomised controlled feasibility
trial with embedded qualitative process evaluation.
Figure 1 shows the schedule of enrolment, interven-
tions and assessments as a SPIRIT figure.
Fig. 1 Testing VOLITION: schedule of enrolment, interventions and assessments
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Sampling
Six GP practices will be recruited from rural Devon and
from each of the cities of Exeter and Plymouth, UK. A
minimum practice size of 3000 patients will ensure suffi-
cient numbers of eligible participants. (It is anticipated
that there will be approximately 800 older patients with
multimorbidity in an average 8000 patient practice [1]).
Table 1 shows the participant inclusion and exclusion
criteria. An average of three (total = 18 GPs), and at
least 2, GPs per practice will be recruited. Patients aged
65 and above with known multimorbidity, defined as the
presence of two or more long-term conditions (as speci-
fied in Table 1), will be approached.
Patient participants will be identified using an auto-
mated practice database search strategy designed by the
research team. The practice administrative team will use
this ‘flag’ to identify ten consecutive potential participants
with pre-booked consultations with each of the three re-
cruited GPs. Random sampling of participants is not
required as the clinical presentations, and therefore the
nature of the decision-making between consecutive con-
sultations, is expected to be random. A total of 180 (mini-
mum 120) potential patients will be identified across 6
practices, with the aim of recruiting at least half.
The sample size is sufficient to compare between-
group differences in quantitative feasibility objectives
such as recruitment rates and data collection procedures
including the completeness of participant questionnaires.
This sample size also allows the estimation of standard
deviations for the clinical outcome measures being
tested. In addition, it is sufficient to obtain a purposively
selected sub-sample of participants for process evalu-
ation interviews, to achieve the qualitative feasibility
objectives.
Recruitment procedures
Non-compliance with the intervention will be taken into
account at patient, GP or practice level by over-
recruiting. Practices will receive email and phone
correspondence inviting their participation. Practice re-
cruitment will be dependent on an expression of interest
from at least two of their GPs. Practices will be incenti-
vised through payment for local coordination and set-
up. GPs will receive a certificate for the training course
(Williamson et al. 2007).
For each recruited GP, ten potential patient participants
with pre-booked appointments will be screened by GPs,
and if eligible, contacted by post ahead of their appoint-
ment. They will receive a cover letter, participant informa-
tion sheet and example consent form. On their arrival in
the practice waiting room, the receptionist will provide
the patient with a pre-consultation questionnaire.
Patients who do not wish to participate will indicate
this with a tick box on the pre-consultation question-
naire. Practices will keep an anonymised log of patients
who declined to participate. A tick box on the post-
consultation questionnaire will enable patients to opt
out of process evaluation interviews and/or from having
their case notes reviewed.
Consent
Written consent from GPs will be obtained at the time
of practice recruitment. Consent to identify and ap-
proach potential patient participants will be obtained
from the practice manager. Written consent from pa-
tients will be obtained by the GP at the start of the con-
sultation. GPs will be expressly clear that they are not
part of the research team when taking consent. Written
informed consent will be obtained prior to interviews for
process evaluation purposes by the Chief Investigator.
Where possible, reasons for participants declining par-
ticipation will be recorded anonymously by the Chief In-
vestigator or by GPs. Identifiable data will not be
accessed without prior patient consent.
Randomisation and blinding
The study will use a cluster randomised design. Clusters
will be defined at practice level, with practices
Table 1 Participant inclusion and exclusion criteria
Participant type Inclusion criteria Exclusion criteria




(GPs will not be excluded based on less than full time working)
Patients Patients aged 65 and above with known multimorbidity
The condition should be one ofa:
angina or long-term heart problem; arthritis or long-term joint
problem; asthma or long-term chest problem; blindness or se-
vere visual impairment; cancer in the last five years; deafness or
severe hearing impairment; diabetes; epilepsy; high blood pres-
sure; kidney or liver disease; long-term back problem; long-term
mental health problem; long-term neurological problem.
Temporary residents and vulnerable patients e.g. those recently
bereaved, those with severe mental illness, severe cognitive
impairment, end stage disease, communication difficulties e.g.
physical impairment caused by a stroke as opposed to language
barriers, a learning disability, or those unable to complete
questionnaires or interviews for any other reason.
(A minimum time for a condition to be ‘long-term’ will not be
specified)
aThis list was adapted from the English National General Practice Patient Survey [10]. Where dyads of conditions occur within the same organ system, e.g. anxiety
and depression, these will only be counted once e.g. mental health problem
Butterworth et al. Pilot and Feasibility Studies           (2020) 6:161 Page 4 of 16
randomised 1:1 to usual care or to the intervention (90
patients per arm) following recruitment. Block random-
isation will be stratified by site; two practices in inner
city Plymouth, two practices from Exeter and two from
rural Devon.
Randomisation will be conducted by an independent
statistician who is blinded to the identity of practices.
Blinding of the research team to outcome assessment
will not be possible due to resource availability. Blinding
of participants is unlikely to be achievable as participants
in the intervention arm are likely to be aware that they
are receiving more than standard ‘usual care’.
The intervention
The overarching project ‘VOLITION’ follows the Inter-
vention Mapping framework ([3]) as a means of system-
atically applying existing literature and relevant theory
to each step of intervention development and evaluation.
Social and behavioural science theory was used to de-
scribe factors affecting older patients’ involvement in
decision-making about their healthcare, as well as
methods for improvement. Evidence from a systematic
review [8], from patient, public and expert opinion and
from a focus group study with older patients with multi-
morbidity and with GPs, enabled the refinement of logic
models underpinning this work. The Intervention Map-
ping process will be published separately.
There are two core intervention components (see
Table 2 and Fig. 2 for detail):
 A patient tool to facilitate patients to convey their
preferences for involvement to the GP
 A workshop for GPs to train them in shared
decision-making orientated communication skills,
delivered in the context of the challenges currently
facing GPs when consulting with this patient group
The patient tool will be mailed to eligible patients ahead
of their index consultation. GPs will attend the training
workshop no earlier than two weeks in advance of the
index consultations with participating patients. Patients in
the usual care group will receive standard care.
Data collection
Practice and participant descriptive data
Practice level data (list size, location and deprivation,
practice size, staffing, rural/urban) and GP participant
data (age, gender, ethnicity and time since qualification)
will be collected at the time of recruitment. Patient
demographics (age, gender and ethnicity) and health sta-
tus data will be collected via self-report using pre-
consultation questionnaires.
Collecting outcome measure data
The General Practice Patient Survey (GPPS) uses five-
point Likert scales [10]. A subset of these are appropri-
ate for evaluation of Patient Reported Outcome Mea-
sures (PROMs) [13] on the pre-consultation patient
questionnaires. These questionnaires will also be used to
collect patients’ pre-consultation preferences for involve-
ment in decision-making.
A post-consultation patient questionnaire will be used
to collect post-consultation PROMs. Data will include
the extent to which patients felt engaged in decision-
making [2], their satisfaction with care and patient em-
powerment [27]. A post-consultation questionnaire for
GPs will collect GPs’ ratings of the extent to which they
felt they involved the patient in decision-making.
Video-recordings will enable the shared decision-
making process to be assessed from an observer perspec-
tive using the OPTION(5) scale (Elwyn 2014). Two re-
searchers will independently score each clinical decision
made out of 100, with higher scores indicating better
shared decision-making.
Case note review by two independent researchers will
take place 12 weeks after the index consultation (to en-
sure time for documentation of the required outcomes).
Information collected will include re-attendance within
28 days and referral for investigation or to secondary
care.
Analysis
Recruitment capability, consent and randomisation
procedures, sample characteristics
The trial will determine whether it is possible to recruit
appropriate study participants to test the intervention,
or whether amendments are required ahead of a future
trial. The flow of participants will be summarised in a
Consort diagram. Numbers of eligible clusters, individual
participants identified and randomised, recruitment rates
and attrition will be recorded.
The search strategy used to identify potentially eligible pa-
tients will be tested on different practice databases with a view
to finalising a generic, universal search algorithm. Anon-
ymised data on ineligible patients will provide a profile of
those frequently excluded. Consideration will be given to
whether adaptations to the trial could be appropriate, to en-
able these patients to participate in a future study.
Any difficulties with meeting recruitment targets (6
practices; at least 2 GPs per practice; at least 5 patients
per GP) will be documented. Field notes and corres-
pondence with practices will enable the issues to be ex-
plored. Patients’ reasons for declining will be reviewed in
light of recruitment procedures. For example, patients
will use the pre-consultation questionnaire to indicate
whether they received the information pack in the post.
The extent to which over-recruitment is necessary will
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Table 2 The VOLITION intervention applications
Patient support toola GP workshop
Central image Delivery and facilitation by a GP
Illustrates the spectrum of patient preferences for involvement
and poses the question “where do you see yourself?”
For the purposes of role-modelling as a means of knowledge transfer
Phrases to use during the consultation Information provision
Aimed at facilitating patients to ask for or decline participation in
decision-making, accompany the central image.
GP-facilitator provides information regarding the elements of a shared decision-making
approach to the consultation, in the context of older patients with multimorbidity.
Phrases are matched to the spectrum of patient preferences for
involvement.
GP-facilitator delivers new messages about the potential benefits of shared decision-
making. GP-facilitator uses a set of one or more meaningful premises and a conclusion to
deliver these messages.
Messages
Inform the patient of their right to ask for involvement in
decision-making about their care.
GP-facilitator provides positive messages regarding the role of the patient and their
preferences within shared decision-making. (This information is designed using evidence
from the literature regarding GPs current beliefs around shared decision-making with this
patient group.)
Suggest that the patient possesses the capability to state their
preferences for involvement to the GP.
GP facilitator provides information about the importance and relevance of a patient-
centred approach to the consultation.
Emphasise the benefits of shared decision-making for the patient. Messages delivered by GP-facilitator suggest that the GP possesses the capability to use a
shared decision-making approach to the consultation.
GPs are asked to relay GP-facilitator’s messages to each other, and facilitator clarifies any
confusion that appears during this process.
Role-play
GPs are first shown an example video-recorded consultation between the GP-facilitator
(peer-model) and an actor-patient. GP-facilitator discusses the challenges of facilitating
shared decision-making with the patient and how (s)he overcame them.
GPs take turns as the GP, the patient and the observer to role-play clinical scenarios in threes.
Individual GPs rehearse and repeat a shared decision-making approach to a role-play consult-
ation, using a new ‘VOLITION’ model, incorporating a patient-centred, holistic approach.
The role-play ‘patient’ states their preference for involvement in decision-making about
their healthcare; their ideas, concerns and expectations; and their preferred data format
for decision-related information. In this way the ‘patient’ prompts the GP to use appropri-
ate communication skills to match their shared decision-making preferences.
Clinical scenarios provide increasingly challenging tasks during role-play, with feedback
from peers serving as an indicator of capability to the GP
GP-facilitator encourages elaboration to augment the information provided in the crib
sheet for the case scenario.
Reflective discussion in threes followed by group feedback
Discussion of GP’s appropriate response to patient preferences, fundamental priorities and
requirements
Discuss the experience and provide feedback to others.
GP-facilitator encourages elaboration to augment the information provided in the crib
sheet for the case scenario.
Supporting reference materials
Handbook containing the VOLITION model and all of the key messages delivered by the
GP-facilitator during the workshop, the case scenarios for role-play and space for the indi-
vidual to write reflective notes. Also available online.
Online link to the video-recorded consultation between GP-facilitator and actor-patient.
Patient dialogue during index consultation
Patient provides a nudge to the GP in the form of a phrase from the patient support tool,
informing the GP of their preferences for involvement in decision making about their care.
Acts as a cue to the GP to adapt their communication skills accordingly.
aThe support tool will also be displayed as a poster in the waiting room to prompt recall, as well as being available in leaflet form.
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be reviewed, as will the importance of incentivising
participants.
Randomisation procedures will be discussed at team
meetings to inform amendments prior to a larger trial. For
example, consideration will be given to randomising more
practices to the intervention than to usual care, to gather
more data regarding intervention implementation if re-
quired. Consideration will be given to initiating the study
in each of the three sites sequentially (e.g. inner city, then
urban, then rural) in order to increase trial management
capacity. Consideration will be given to blinding the re-
search team for data analysis in the future trial.
Rates of patient consent, to the use of questionnaire
data, to video-recording ([12]; Asan and Montague
2014) and to case note review, will be evaluated. Num-
bers lost to follow-up will be reviewed; however, it is an-
ticipated that this will be minimal. The study will
determine whether there are differential drop-out or re-
cruitment rates between intervention and control groups
(indicative of selection bias).
The degree of sociodemographic diversity in the sam-
ple will be reported in respect of generalisability of re-
sults. The external validity of the sample will be
reviewed by comparing to relevant external datasets
when reporting recruitment, selection procedures and
participation rates (Steckler and McLeroy 2007).
Evaluation of data collection
Table 3 outlines the feasibility measures to be assessed
regarding the collection of outcome data.
The study will assess the appropriateness of data collec-
tion procedures for use in the intended participant popu-
lation as well as for the purposes of evaluating the
intervention. Field notes from the research team, process
evaluation interviews with participants and research meet-
ing notes will guide an assessment of the appropriateness
of measures. Participants’ ability to complete each patient-
facing or GP-facing measure will be reviewed.
Assessments of the volume of data collection will es-
tablish whether it is appropriate to scale-up in a larger
trial. This will include the time taken for field visits, data
input and independent checking of the trial database.
Overall completeness of data will be established, along
with the impact of this on the potential usability of data
to evaluate the effectiveness of the intervention.
Fig. 2 The VOLITION intervention
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Evaluation of outcome measures
Table 4 shows the data to be collected from patients,
GPs and practices for comparability of outcome mea-
sures between randomised groups, along with methods
of analysis. Analysis will be of observed data only (no
statistical methods for addressing missing outcome data,
such as multiple imputation, will be used). However, the
study will report on reasons for missing outcome data.
Any between-group differences, indicating bias, will be
evaluated. These evaluations will inform the methods of
analysis of both dependent and explanatory outcome
variables in the future trial, as well as a review of cost
and resource implications. Examples of potential reasons
for missing data include loss to follow-up, participants’
completion of questionnaires but non-attendance at the
Index consultation, participants attending the consult-
ation but not providing data on questionnaires, data lost
or unavailable for other reasons, participants no longer
able to experience post-consultation outcomes for ex-
ample because they have died.
Using an ‘intention to treat’ approach, participants will
be analysed according to their randomised allocation irre-
spective of intervention actually received. However, all
participants will be considered adherent by definition of
the protocol. There is no mechanism by which partici-
pants in the control group could receive the intervention.
An intra-cluster correlation coefficient (ICC) will be
calculated within each arm (intervention and control)
for academic purposes; however, this will not be used to
calculate a sample size for the future definitive trial; an
estimated ICC, calculated from a large relevant routine
dataset, will instead be sought [40].
The appropriateness of the outcome measures for use
in a future, definitive trial of the intervention will be
evaluated. The consistency with which certain outcome
measures (e.g. OPTION(5), CollaboRATE, and those
items taken from the GPPS survey) perform with the
study population, when compared with previous per-
formance in existing literature, will be reviewed. Find-
ings will also be considered in the context of the internal
consistency of performance of these measures within the
participant sample. Consideration will be given as to
whether the outcome measures chosen are sensitive to
the effects of the intervention in the context of older
people with multimorbidity in primary care, or whether
there is a need for development of new measures.
Evaluation of resources and capacity to manage the study
and implement the intervention
A cost-effectiveness framework for a subsequent defini-
tive trial will be developed by identifying, measuring and
valuing the resources used to deliver the intervention.
For example, the time required to identify ten consecu-
tive eligible patients per GP will contribute to informing
the time required for intervention delivery in the future
trial. Data collection processes will be tested with con-
sideration of estimations of the size and range of cost
components, along with reporting of the resource use
categories prone to missing data. For example, the ac-
ceptability of administering questionnaires will be ana-
lysed by reporting missing values and presenting mean
scores and 95% confidence intervals.
Patient safety data will be described numerically in
both intervention and control practices (no hypothesis
testing), e.g. hospital admissions, attendances at A&E
and deaths within 7 days of the index consultation.
Preliminary evaluation of participant responses to the
intervention
The intended sample size is sufficient to estimate stand-
ard deviations in our intended primary outcome, ‘ratings
of shared decision-making during the consultation from
an observer perspective’, for the intervention and control
group. This outcome data will be obtained from OP-
TION(5) ratings of video-recorded consultations. No
formal power calculations will be carried out and hy-
pothesis testing will not be appropriate [47].
The observer OPTION(5) scores (Elwyn 2014) and the
patient and GP ratings of shared decision-making, based
on collaboRATE (Elwyn 2014), will be analysed using
hierarchical linear modelling with a random effect on
cluster. Patient and GP collaboRATE scores will be com-
pared using logistic regression; modelling patient scores
as the outcome and GP scores as the explanatory vari-
able, providing preliminary data on whether patient and
GP perceptions are congruent.
Patients vary in their pre-existing preferences for in-
volvement in decision-making about their healthcare
(Butterworth 2013 [50];). A secondary analysis with ad-
justment for patients’ reported preference for shared
decision-making will provide a preliminary indication as
to whether patients’ pre-existing preferences influence
the effect of the intervention.
The participant population will be ‘all randomised’ and
the analysis strategy will be ‘intention to treat’. There are
no plans for interim analysis.
Process evaluation using qualitative methods
A qualitative interview study, embedded within the feasi-
bility trial with data integration.
Fifteen patients from intervention practices will be
sampled and twice this number will be approached. Pa-
tients will be selected purposively and iteratively, using
questionnaire data to ensure heterogeneity by age, socio-
demographic characteristics, health status and prefer-
ence for shared decision-making (Coyne 2008). Patients
will be contacted by telephone to arrange an interview.
All GPs in the intervention group will be invited by
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Components to be reviewed Methods of analysis Potential resultant amendments ahead
of a definitive, larger trial
Patient-facing
(questionnaires)
All patient-facing data collection forms
have been reviewed for their suitability
by Patient and Public Involvement (PPI)
group
PPI members advised on the wording
and format of questionnaires. PPI will
provide a lay perspective on
interpretation of feasibility findings.
The feasibility of distribution and
collection of patient questionnaires by
receptionists.
Researcher’s field notes and follow-up
correspondence with practices.
Process evaluation interviews with
patients.
Consideration of distribution by another
means e.g. in the post (or email) prior to
consultation.
The appropriateness of collecting
demographic data by patient self-report
on pre-consultation questionnaires, as op-
posed to through the medical record.
Review of completeness of relevant items
on patient questionnaires. Process
evaluation interviews to discuss potential
reasons for missing data.
Correspondence with practices regarding
practicalities of accessing patient
demographic data with consent.
Consideration of accessing patient
baseline data through practice records.
Whether patient participants require
assistance, encouragement or supervision
to complete either of the questionnaires.
Researcher’s field notes and process
evaluation interviews.
The provision of assistance to patients
when completing questionnaires, e.g.
providing staff to assist them or allowing
more time pre- or post-consultation to
allow the patient to seek help from a
third party.
Issues regarding time taken for
questionnaire completion, any difficulties
with comprehension of questionnaire
items, numbers of questionnaires
returned and reasons for missing data
Relevant quantitative data will be
reported descriptively. Issues will be
explored qualitatively with patients
during process evaluation.
Time taken for completion may inform
decisions surrounding when and how to
distribute questionnaires. Issues regarding
comprehension of specific items may lead






Issues regarding time taken for
consenting patients, any difficulties with
comprehension of items and reasons for
missing data
Relevant quantitative data will be
reported descriptively. Issues will be
explored qualitatively with GPs during
process evaluation.
Amendments to wording of consent
form. Re-costing of incentive payments to
practices if necessary, for extra consult-
ation time to allow for consent.
Issues regarding operation of video-
camera to record consultation
Rates of incomplete, unusable or missing
recordings will be reported. Issues will be
explored qualitatively with GPs during
process evaluation, through the
researcher’s field notes and through
correspondence with practices regarding
any setup difficulties.
Review of existing technology and
equipment provided, consideration of the
need for prompts for GPs to initiate
videos
Issues regarding time taken for
questionnaire completion, any difficulties
with comprehension of questionnaire
items, numbers of questionnaires
returned and reasons for missing data
Relevant quantitative data will be
reported descriptively. Issues will be
explored qualitatively with GPs during
process evaluation.
Issues regarding comprehension of
specific items may lead to rewording. Re-
costing of incentive payments to practices





The ability of members of the research
team, to complete OPTION(5) score
sheets based on review of video-recorded
consultations.
Inter-rater reliability of OPTION(5) scores
will be evaluated by calculating the inter-
class correlation coefficient on ratings of
all videos, aiming for values above 0.75.
Comparisons will be made with other
studies.
The completeness and usability of video-
recordings will also be reviewed as de-
scribed above.
Review of training procedures for
OPTION(5) measure if correlation low.
Review of appropriateness of the measure
in the context of this study if training
appears sufficient. Consideration of the
need for development of an alternative
measure to be piloted ahead of a
definitive trial.
The case note template will be assessed
for usability.
Any difficulties with comprehension of
items by the research team will be
reviewed in team meetings.
Any challenges when obtaining the
information required on case note review
forms, including accessing and
interpreting the information from the
Re-wording and re-formatting of the
template.
Review of the qualifications required by
the research team e.g. clinical academics
only and level of qualification if so.
Consideration of time frame for data
collection, e.g. is 28 days sufficient to
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email. The sample size will be reviewed when assessing
thematic saturation [22].
Following receipt of post-consultation participant
questionnaires, semi-structured interviews aided by a
topic guide will be digitally audio recorded, transcribed
and supported by field notes. Participants will be en-
couraged to discuss their own ideas in order to collect
fresh data without the influence of the researcher (Brit-
ten et al. 1995). Data will be collected regarding:
Participant experiences of the intervention
 Acceptability of the intervention
 Influences for intervention implementation and
integration into normal practice
 Whether participants perceive the intervention to be
effective
Participant experiences of the study
 How study participation was experienced
 Whether study participation induced behaviour
change not prescribed by the intervention
Audio recordings will be coded using Nvivo computer
software (Mills, Bonner and Francis 2006). Data analysis
will take a sequential-explanatory approach, combining
both deductive and inductive methods to investigate
whether the theory developed earlier in the project
holds, but also being open to new data and emerging
themes [31]. The concept of inductive thematic satur-
ation [21] (Maykut and Morehouse 1994) will be applied
and negative cases will be actively sought [44]. The
consistency with which the coding is applied will be
assessed on a fifth of the data [29]. Analytic meetings
will be held with the research team to discuss validity.
Data will be interpreted within the context of possible
cause–effect pathways of the intervention.
Criteria for progression to a future definitive randomised
controlled trial of the intervention
Study processes are designed to be iterative, formative
and adaptive [6]. However, there are certain criteria on
which progression to a future, larger trial of intervention
effectiveness is dependent. These are:
 Recruitment
 > 80% of general practices approached (i.e. 5/6)
 > 60% of GPs approached per practice (i.e. 2/3)
 > 50% of patients approached per practice (i.e.
20/30)
 Collection of outcomes
 > 60% of patient-reported outcomes (question-
naire response rate)
 > 70% of patient questionnaire respondents
providing written consent to case-note review
 > 70% of video recordings useable for observer
ratings
Loss to follow up is expected to be minimal and is
therefore not included as a ‘stopping criteria’.
The Chief Investigator, the Trial Steering Committee
and the sponsor have the authority to stop or advise
modifications to the feasibility trial.
Data management, trial monitoring and participant safety
The Data Management Plan and Data Privacy Impact
Assessment are included in the Appendix. Monitoring
will be carried out by the Trial Steering Committee in
conjunction with the Chief Investigator and the super-
visory team. Prospective, planned deviations or waivers
to the protocol are not allowed under the UK regula-
tions on Clinical Trials and must not be used. Accidental
protocol deviations will be adequately documented, re-
ported to the Chief Investigator, sponsor and ethics
committee as indicated.
Indemnity
Both University of Exeter indemnity arrangements and
National Health Service indemnity apply.
Dissemination
Findings will be published in a peer-reviewed journal,
disseminated to participants via GP practices and pre-
sented at relevant local and national conferences. The






Components to be reviewed Methods of analysis Potential resultant amendments ahead
of a definitive, larger trial
patient’s medical record, will be reviewed
at team meetings.
Inter-rater reliability for items on the case
note review form will be evaluated by
calculating an ICC on 20% of the data.
allow the notes to ‘settle’ and to capture
all relevant documentation.
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Table 4 Evaluation of outcome measure processes
Data Timing of data
collection










Practice characteristics (list size,
location, deprivation)












(random effect on cluster,
adjustment for practice
location).














(random effect on cluster,
adjustment for practice
location).












Mean and standard deviation,
to report data descriptively.
Linear hierarchical modelling
to estimate between group
differencesa (random effect
on cluster, adjustment for
practice location).








































Ratings of shared decision-
making during the consultation
from an observer perspective.














Mean and standard deviation,
to report data descriptively.
Linear hierarchical modelling
to estimate between group
differences* (random effect


















Mean and standard deviation,
to report data descriptively.
Linear hierarchical modelling
to estimate between group
differencesa (random effect
on cluster, adjustment for
practice location).
Patient and GP scores
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Table 4 Evaluation of outcome measure processes (Continued)
Data Timing of data
collection











scores as outcome, GP scores
as explanatory variable).
Patient-reported rating of feeling


















(random effect on cluster,
adjustment for practice
location).
Patient-reported rating of having






















(random effect on cluster,
adjustment for practice
location).
GP-reported rating of their

















Mean and standard deviation,
to report data descriptively.
Linear hierarchical modelling
to estimate between group
differencesa (random effect
on cluster, adjustment for
practice location).
Patient and GP scores
compared using logistic
regression modelling (patient
scores as outcome, GP scores
as explanatory variable).
Patient contacts in a 28-day
period following the index con-
sultation, including the nature of
contact with the GP surgery, the
hospital admissions, A&E atten-
dances. If patient moved away




(to allow time for
contacts to be recorded
in the notes)









(random effect on cluster,
adjustment for practice
location).
Deaths within a seven day
period following the index
consultation; death within 28




(to allow time for
contacts to be recorded
in the notes)

















(to allow time for







Frequencies, to report data
descriptively.
Logistic hierarchical
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international guidelines from the International Commit-
tee of Medical Journal Editors will be applied.
The University of Exeter has a dedicated Research and
Knowledge Transfer team to identify, evaluate and com-
mercialise any Intellectual Property resulting from this
research.
Discussion
Shared decision-making during general practice consul-
tations for older people with multimorbidity is currently
under-researched and poorly understood [8]. However,
emerging clinical guidelines for the management of mul-
timorbidity have advised on a personalised, patient-
centred approach when balancing the risks and benefits
of treatment; to reduce treatment burden, and to focus
on quality of life as well as on specific disease control
[33, 34]. The Royal College of General Practitioner, to-
gether with NHS England, have a current focus on
shared decision-making as a core component of a train-
ing programme to deliver personalised care to patients
in England [35, 41].
Comparisons with existing literature
There is currently no firm evidence about the most ef-
fective types of intervention for increasing healthcare
professionals’ adoption of shared decision-making; how-
ever, studies advocate targeting patients and practi-
tioners together [24]. A review of three randomised
controlled trials of interventions to improve older pa-
tients’ involvement in primary care consultations [50]
suggested using face-to-face sessions to encourage prac-
titioner behaviour change along with a written support
tool for patients. The review authors advised evaluation
using randomised controlled trials, using objective health
outcomes over time, a valid assessment from patient, GP
and observer perspectives and to correct results for
patients’ reported preferences for involvement. A more
recent review [8] suggested that transparency in inter-
vention design, testing and evaluation is required to in-
form the evidence base.
Strengths and limitations of the study
The systematic development, testing and evaluation of
an intervention in this field of research is warranted and
timely.
Resources for this doctoral fellowship study are lim-
ited, as is researcher capacity, and therefore the partici-
pant sample is from one county in the UK only. The
patient population in Devon is predominantly of white
ethnicity. Consideration will be given to targeting pa-
tients of black and other ethnic minorities; however, in
some rural areas of Devon, numbers are expected to be
limited. Devon also has a higher proportion of older
people when compared with the rest of the UK. This
may give a false impression of the feasibility of patient
recruitment and consideration will be given to this when
reporting generalisability of findings. However, GP prac-
tices in inner city Plymouth are being targeted with the
aim of accessing areas of social deprivation, as well as
ethnic diversity.
The findings from this study will inform the decision
to progress to a full-sized randomised controlled trial.
Quantitative feasibility measures are complimented by
qualitative process evaluation, enabling the exploration
of both patient and GP participant perceptions of study
processes, and to gain insight into barriers and facilita-
tors for successful implementation of the intervention.
If found to be feasible, the future trial design will be
adapted to take account of any challenges encountered
in this study, to optimise trial processes including re-
cruitment and data collection. Certain challenges are ex-
pected. For example, UK GPs, who are currently under
Table 4 Evaluation of outcome measure processes (Continued)
Data Timing of data
collection











contacts to be recorded
in the notes)
of change modelling to estimate
between group differencesa




Participant experiences of the
intervention, participants
















Both deductive and inductive
approaches to thematic
analysis
aBetween group differences will be reported using the appropriate outcome metric with 95% confidence intervals; no p-values will be reported in this
feasibility study
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considerable workload pressure, may be difficult to re-
cruit. Incentivisation to participate will be used and
process evaluation will enable an understanding of
whether this was successful. It is also expected that cer-
tain vulnerable patient groups, such as those with de-
mentia and those suffering a terminal illness, will be
excluded. Consideration will be given as to how vulner-
able patients, to whom personalised care is particularly
important, could be included in a future trial. For ex-
ample, the involvement of third-party carers during the
consultation will be explored.
The study informs the choice of appropriate good-
quality outcome measures for a future trial. The feasibil-
ity study is not powered to evaluate intervention effect;
however, it is designed to avoid the problem of wasted
time and resources which might otherwise occur if data
collection and evaluation processes were not tested.
This project seeks to fill the current gap in the litera-
ture, to inform clinicians and policy makers in their
provision of good-quality patient-centred care of older
people with multimorbidity. The research team are well-
placed within both clinical and academic primary care to
carry out the work, and they have the skills and experi-
ence required to complete the proposed study.
Roles and responsibilities of trial management groups
and individuals
The project planning group
Key contributors include two representatives of the pa-
tient and public involvement (PPI) group; two practicing
GPs; a clinical commissioner; two professors in the field
of Primary Care research; a professor of Clinical Com-
munication with qualitative research expertise; a profes-
sor in Psychology Applied to Health with experience of
Intervention Mapping; members of the Exeter Clinical
Trials Unit; a trials statistician; a post-doctoral re-
searcher, with expertise in PPI; international experts in
the fields of shared decision-making, multimorbidity,
and intervention mapping approaches.
Trial steering committee
The Trial Steering Committee (TSC) oversees the pro-
ject milestones, addresses any barriers to study comple-
tion and any reasons why the study should not continue.
The TSC ensure that the conduct of the study safe-
guards the safety, rights and wellbeing of participants.
The TSC absorbs the role of Data Management Ethics
Committee.
Sponsors representative
Mrs Pam Baxter, Senior Research Governance Officer,
University of Exeter, Lafrowda House, St Germans Road,
Exeter, Devon, EX4 6TL. p.r.baxter2@exeter.ac.uk.
01392 723588.
Patient and public involvement
The National Institute for Health Research (NIHR) Col-
laboration for Leadership in Applied Health Research
and Care, South West Peninsula (PenCLAHRC), assisted
with the identification of a group of eight older members
of the public with varying, ages, sex, degrees of morbid-
ity and health service experiences. Members of the
group remain involved in prioritising and designing
intervention and study materials. They provide a lay per-
spective on emerging findings.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40814-020-00699-7.





The Chief Investigator is the primary author and primary contributor to the
study design, conduct, data analysis and interpretation, manuscript writing
and dissemination of results. The supervisory team (JC, SR and EP) along
with the trial statistician (FW) have provided feedback and suggested
amendments to the study design and protocol during and since the funding
application process. Neither the study sponsor nor funder have contributed
to study design and are not expected to contribute to study conduct, data
analysis/interpretation or writing and dissemination of results. The funder has
approved the study protocol and the sponsor has provided final sign-off at
the point of application for ethics approval. The authors read and approved
the final manuscript.
Funding
National Institute for Health Research UK. Address: Leeds Office, 21 Queen
Street, Leeds, LS1 2TW
Phone: 0113 343 2314
Fax: 0113 343 0336. Funders number: DRF-2017-10-005. Amount awarded:
£430,304.00 for the overarching doctoral fellowship project; of which this
study forms the largest of three work packages.
Availability of data and materials
Not applicable—protocol only.
Ethics approval
The trial received ethical approval from HRA and Health and Care Research
Wales (HCRW) IRAS ref. 253014 on 21st July 2019.
Consent for publication
There are no plans to share the raw data from this study and participants
will not be consented to do so. Observations from consultations, data from
patient notes and/or quotes from participant interviews may be reproduced
in reports and papers, but the participant’s identity will be kept anonymous.
Participants will be consented for this.
Competing interests
The authors declare that they have no competing interests.
Author details
1Exeter Collaboration for Academic Primary Care (APEx), University of Exeter
Medical School, Room 110, Smeall building, St Luke’s campus, Magdalen
Road, Exeter EX1 2LU, UK. 2Leeds Institute of Health Sciences, School of
Medicine, University of Leeds, Leeds, UK.
Butterworth et al. Pilot and Feasibility Studies           (2020) 6:161 Page 14 of 16
Received: 7 October 2019 Accepted: 29 September 2020
References
1. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology
of mulitmorbidity and implications for healthcare, research, and medical
education: a cross-sectional study. Lancet. 2012;380(9836):37–43.
2. Barr PJ, Thompson R, Walsh T, Grande S, Ozanne E, Elwyn G. The
psychometric properties of CollaboRATE: a fast and frugal patient-reported
measure of the shared decision-making process. J Med Internet Res. 2014;
16(1):e2.
3. Bartholomew LK, Parcel GS, Kok G, Gottlieb NH, Fernandez ME. Planning
health promotion programs: an intervention mapping approach. London:
Willey Press; 2011.
4. Bastiaens H, Van Royen P, Pavlic DR, Raposo V, Baker R. Older people's
preferences for involvement in their own care: a qualitative study in primary
health care in 11 European countries. Patient Educ Couns. 2007;68(1):33–42.
5. Berkelmans PGJ, Berendsen AJ, Verhaak PFM, van der Meer K. Characteristics
of general practice care: what do senior citizens value? A qualitative study.
BMC Geriatr. 2010;10(80) Available: www.biomedcentral.com/1471-2318/10/
80, [01 Nov 2015].
6. Bowen DJ, Kreuter M, Spring B, Cofta-Woerpel L, Linnan L, Weiner D, et al.
How we design feasibility studies. Am J Prev Med. 2009;36:452–7.
7. Bowling A, Rowe G, McKee M. Patients' experiences of their healthcare in
relation to their expectations and satisfaction: a population survey. J R Soc
Med. 2013;106(4):143–9.
8. Butterworth JE, Hays R, Mcdonagh STJ, Richards SH, Bower P, Campbell J.
Interventions for involving older patients with multi-morbidity in decision-
making during primary care consultations. Cochrane Database Syst Rev.
2019;10 https://doi.org/10.1002/14651858.CD013124.pub2.
9. Butterworth JE, Campbell JL. Older patients and their GPs: shared decision
making in enhancing trust. Br J Gen Pract. 2014;64(628):e709–18.
10. Campbell J, Smith P, Nissen S, Bower P, Elliott M, Roland M. The GP patient
survey for use in primary care in the National Health Service in the
UK—development and psychometric characteristics. BMC Fam Pract. 2009;
10(57) Available: http://www.biomedcentral.com/1471-2296/10/57 [01 Nov
2015].
11. Cassell A, Edwards D, Harshfield A, Rhodes K, Brimicombe J, Payne R. et al.,
‘The epidemiology of multimorbidity in primary care: a retrospective cohort
study’. Br J Gen Pract. 2018;86:e245–51.
12. Coleman T. Using video-recorded consultations for research in primary care:
advantages and limitations. Fam Pract. 2000;17(5):422–7.
13. Croker JE, Swancutt DR, Roberts MJ, Abel GA, Roland M, Campbell JL.
Factors affecting patients' trust and confidence in GPs: evidence from the
English national GP Patient Survey. BMJ Open. 2013;3(5):e002762.
14. Department of Health (2013) Liberating the NHS: no decision about me,
without me, Available: https://www.gov.uk/government/uploads/system/
uploads/attachment_data/file/216980/Liberating-the-NHS-No-decision-
about-me-without-me-Government-response.pdf [02 Nov 2015].
15. Department of Health (2012) Long term conditions compendium of
information: Third Edition, Available:https://www.gov.uk/government/
uploads/system/uploads/attachment_data/file/216528/dh_134486.pdf
[02Nov 2015].
16. Department of Health (2011) Atlas of variation, Available: https://www.
rightcare.nhs.uk/index.php/atlas/atlas-of-variation-2011 [02 Nov 2015].
17. Drennan V, Walters K, Lenihan P, Cohen S, Myerson S, Iliffe S. Priorities in
identifying unmet need in older people attending general practice: a
nominal gorup technique study. Fam Pract. 2007;24(5):454–60.
18. Elwyn G, Barr PJ, Grande SW, Thompson R, Walsh T, Ozanne EM. Developing
CollaboRATE: a fast and frugal patient-reported measure of shared decision
making in clinical encounters. Patient Educ Couns. 2013a;93(1):102–7.
19. Elwyn G, Tsulukidze M, Edwards A, Légaré F, Newcombe R. Using a ‘talk’
model of shared decision making to propose an observation-based
measure: Observer OPTION5 Item. Patient Educ Couns. 2013b;93(2):265–71.
20. Flocke SA, Miller WL, Crabtree BF. Relationships between physician practice
style, patient satisfaction, and attributes of primary care. Fam Pract. 2013;
51(10):835–40.
21. Glaser BG, Strauss AL. The discovery of grounded theory. Chicago, IL:
Aldine; 1967.
22. Green J, Thorogood N. Qualitative methods for health research. 2nd ed.
California USA: Sage; 2009.
23. Kiesler DJ, Auerbach SM. Optimal matches of patient preferences for
information, decision-making and interpersonal behavior: Evidence, models
and interventions. Patient Educ Couns. 2006;61(3):319–41.
24. Légaré F, Stacey D, Turcotte S, Cossi MJ, Kryworuchko J, Graham ID, Lyddiatt
A, Politi MC, Thomson R, Elwyn G, Donner-Banzhoff N. Interventions for
improving the adoption of shared decision making by healthcare
professionals. Cochrane Database Syst Rev. 2014;9:CD006732.
25. Loh A, Leonhart R, Wills CE, Simon D, Härter M. The impact of patient
participation on adherence and clinical outcome in primary care of
depression. Patient Educ Couns. 2007;65(1):69–78.
26. Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A,
Meinow B, Fratiglioni L. Aging with multimorbidity: a systematic review of
the literature. Ageing Res Rev. 2011;10(4):430–9.
27. McAllister M, Dunn G, Payne K, Davies L, Todd C. Patient empowerment: the
need to consider it as a measurable patient-reported outcome for chronic
conditions. BMC Health Serv Res. 2012;12:157 Available: http://www.
biomedcentral.com/1472-6963/12/157 [03 Nov 2015].
28. McBride D, Hardoon S, Walters K, Gilmour S, Raine R. Explaining variation in
referral from primary to secondary care: cohort study. BMJ Open. 2010;
341(c6267) Available: https://doi.org/10.1136/bmj.c6267 [03 Nov 2015].
29. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med. 2012;
22(3):276–82.
30. Melzer D, Tavakoly B, Winder RE, Masoli JAH, Henley WE, Ble A, Richards SH.
More medicine for the oldest old: observational study in general practice
records 2003 to 2011. Age Ageing. 2014. https://doi.org/10.1093/ageing/
afu113 [02 Dec 2015].
31. Moore, et al. Process evaluation of complex interventions: Medical Research
Council guidance. Br Med J. 2015;35(h1258).
32. Mujica-Mota RE, Roberts M, Abel G, Elliott M, Lyratzopoulos G, Roland M,
Campbell J. Common patterns of morbidity and multimorbidity and their
impact on health-related quality of life: evidence from a national survey.
Qual Life Res. 2015;24(4):909–18.
33. Muth C, van den Akker M, Blom JW, Mallen CD, Rochon J, Schellevis FG, et
al. The Ariadne principles: how to handle multimorbidity in primary care
consultations. BMC Med. 2014;12(1):223.
34. National Institute for Health and Care Excellence. Multimorbidity: clinical
assessment and management: National Institute for Health and Care Excellence;
2016. Available: https://www.nice.org.uk/guidance/ng56 [14 Sept 2020].
35. NHS England. (2019) Universal personalised care: implementing the
Comprehensive Model [online], Available: https://www.england.nhs.uk/
publication/universal-personalised-care-implementing-the-comprehensive-
model/ [14 Sept 2020].
36. NHS Information Centre. (2009) Trends in consultation rates in general
practice 1995 to 2008: analysis of the Q Research® database [online],
Available: https://catalogue.ic.nhs.uk/publications/primary-care/general-
practice/tren-cons-rate-gene-prac-95-09/tren-cons-rate-gene-prac-95-09-95-
08-rep.pdf [03 Nov 2015].
37. Ommen O, Thuem S, Pfaff H, Janssen C. The relationship between social
support, shared decision-making and patient's trust in doctors: a cross-
sectional survey of 2,197 inpatients using the Cologne Patient
Questionnaire. Int J Public Health. 2011;56(3):319–27.
38. Peters RM. Matching physician practice style to patient information issues and
decision-making preferences. An approach to patient autonomy and medical
paternalism issues in clinical practice. Arch Fam Med. 1994;3(9):760–3.
39. Quiñones AR, Botoseneanu A, Markwardt S, Nagel CL, Newsom JT, Dorr DA,
et al. Racial/ethnic differences in multimorbidity development and chronic
disease accumulation for middle-aged adults. PLoS One. 2019;14:e0218462.
40. Richards DA, Hallberg IR. Complex interventions in health. An overview of
research methods. 1st ed. Abingdon UK: Routledge; 2015.
41. Royal College of General Practitioners (2019). The RCGP curriculum. The
curriculum topic guides. Available: https://www.rcgp.org.uk/training-exams/
training/gp-curriculum-overview/document-version.aspx [14 Sept 2020].
42. Royal College of General Practitioners (2013). The 2022 GP compendium of
evidence, Available: http://www.rcgp.org.uk/~/media/Files/Policy/A-Z-policy/
The-2022-GP-Compendium-of-Evidence.ashx [20 Oct 2015].
43. Salisbury C, Johnson L, Purdy S, Valderas JM, Montgomery AA.
Epidemiology and impact of multimorbidity in primary care: a retrospective
cohort study. Br J Gen Pract. 2011;61(582):e12–21.
44. Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, Burroughs H,
Jinks C. Saturation in qualitative research: exploring its conceptualization
and operationalization. Qual Quant. 2018;52:1893–907.
Butterworth et al. Pilot and Feasibility Studies           (2020) 6:161 Page 15 of 16
45. Singer L, Green M, Rowe F, Ben-Shlomo Y, Morrissey K. Social determinants
of multimorbidity and multiple functional limitations among the ageing
population of England, 2002–2015. SSM Popul Health. 2019;8:100413.
46. Tate AR, Nicholson A, Cassell JA. Are GPs under-investigating older patients
presenting with symptoms of ovarian cancer? Observational study using
General Practice Research Database. Br J Cancer. 2010;102(6):947–51.
47. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, Robson R, Thabane M,
Giangregorio L, Goldsmith CH. A tutorial on pilot studies: the what, why
and how. BMC Med Res Methodol. 2010;10(1) Available: http://www.
biomedcentral.com/1471-2288/10/1 [03 Nov 2015].
48. Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common
chronic condition--multimorbidity. JAMA. 2012;307(23):2493–4.
49. van den Brink-Muinen A, van Dulmen SM, de Haes HC, Visser AP, Schellevis
FG, Bensing JM. Has patients' involvement in the decision-making process
changed over time? Health Expect. 2006;9(4):333–4.
50. Wetzels R, Harmsen M, Van Weel C, Grol R, Wensing M. Interventions for
improving older patients’ involvement in primary care episodes. Cochrane
Database Syst Rev. 2008;24(1):CD004273.
51. World Health Organization (1994). A declaration on the promotion of
patients' rights in Europe, Available: http://www.who.int/genomics/public/
eu_declaration1994.pdf [03 Nov 2015].
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Butterworth et al. Pilot and Feasibility Studies           (2020) 6:161 Page 16 of 16
